First Hawaiian Bank Nektar Therapeutics Transaction History

First Hawaiian Bank

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2019 Jul 15, 2019	SELL	$31.0 - $36.3 $6,510 - $7,622	-210 Closed	0 $0
Q1 2019 Apr 02, 2019	SELL	$31.58 - $46.35 $8,368 - $12,282	-265 Reduced 55.79%	210 $7,000
Q4 2018 Jan 11, 2019	SELL	$30.43 - $56.65 $22,822 - $42,487	-750 Reduced 61.22%	475 $16,000
Q3 2018 Oct 16, 2018	BUY	$46.46 - $68.49 $56,913 - $83,900	1,225 New	1,225 $75,000

145

139M

32.6K

14.1K

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $174M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

Get notified when there are updates to the investment portfolio of First Hawaiian Bank, based on Form 13F filings with the SEC.

Stay updated on First Hawaiian Bank with notifications on news.